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36Objective: To determine the response rate, toxicity, and rate of complete resection after induction chemoradio-
therapy for locally advanced thymic tumors, which were defined by specific radiographic criteria.
Methods: A single-arm, pilot trial was conducted at 4 institutions. Patients with thymoma or thymic carcinoma
who met specific criteria on computed tomography were accrued. Induction therapy consisted of 2 cycles
of cisplatin and etoposide combined with 45 Gy of thoracic radiotherapy. Patients underwent computed
tomography and positron emission tomography before and after induction therapy and then resection was
attempted. Postoperative chemoradiotherapy was administered in selected patients. The primary endpoint
was the pathologic response to induction therapy. The secondary endpoints were toxicity, surgical complica-
tions, radiographic response, and the rate of R0 resection.
Results:A total of 22 patients were accrued during a 5-year period (1 patient withdrew before starting induction
therapy). Of the 22 patients, 21 completed induction therapy, and 9 (41%) experienced grade 3 or 4 toxicity. A
total of 10 patients had a partial radiographic response and 11 had stable disease. Of the 21 patients, 17 (77%)
underwent an R0 resection, 3 (14%) an R1 resection, and 1 (5%) underwent debulking. Eight patients sustained
surgical complications (36%), and two patients (9%) died postoperatively. Of the 21 patients, 13 (62%) had
either thymic carcinoma or B3 thymoma and 15 (71%) had either Masaoka stage III or IV disease. No patient
had a complete pathologic response, but 5 specimens (24%) had<10% viable tumor.
Conclusions: The present induction chemoradiotherapy protocol, which used specific computed tomography
inclusion criteria to successfully select locally advanced thymic tumors, appeared to be tolerable and resulted
in a high rate of complete surgical resection. (J Thorac Cardiovasc Surg 2014;147:36-46)Supplemental material is available online.e Daniel and Gloria Blumenthal Cancer Center,a Paramus, NJ; Division of
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The Journal of Thoracic and Cardiovascular SurgeLocally advanced thymic epithelial tumors have a signifi-
cant risk of recurrence after surgical resection, in part,
because of the inability to perform a complete resection
in approximately 50% of cases.1 Because these tumors
have been documented to be chemoresponsive, attempts
have been made to increase the resectability of locally
advanced thymic tumors using induction chemotherapy.
Thus, several retrospective reports and phase II clinical
trials with small numbers of patients have been published
with results suggesting that the addition of chemotherapy
before resection for stage III and IVA thymic tumors might
enhance the ability to perform a complete resection
with acceptable toxicity compared with historical
controls.1-7 Despite this, the lack of specific inclusion
criteria for these studies has made the comparison of
tumor characteristics among the reports impossible.
Given that thymic tumors are also sensitive to radio-
therapy,8 combined with the importance of complete
resection in patient treatment, we designed a prospective,
phase II, pilot clinical trial to evaluate the addition of
radiotherapy to chemotherapy before resection. Specific
radiographic inclusion criteria were also proposed to
facilitate the comparison of these trial results with future
studies. The purpose of the present trial was to documentry c January 2014
Abbreviations and Acronyms
CPR ¼ complete pathologic response
CT ¼ computed tomography
ITMIG ¼ International Thymic Malignancy
Interest Group
PET ¼ positron emission tomography
SUVmax ¼ maximum standardized uptake value
WHO ¼ World Health Organization
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chemoradiotherapy, evaluate the toxicity and surgical
outcomes, assess the ability of specific radiographic
inclusion criteria to predict the tumor stage and histo-
logic type, and document the recurrence patterns and
survival.METHODS
Clinical Trial Design
A single-arm, prospective, pilot clinical trial (NCT00387868) was
conducted at 4 institutions and was approved by all 4 institutional review
boards. A single site served as the data management center, where the
trial was reviewed regularly by the data safety monitoring board. The
present trial evaluated an induction therapy regimen of concurrent
chemoradiotherapy followed by surgical resection for locally advanced
thymic tumors confined to the mediastinum. The study schema is shown
in Figure 1.
Patient Population and Inclusion Criteria
Patients 18 years old with a Karnofsky performance status of 80%
who presented with previously untreated, biopsy-proven thymoma or
thymic carcinoma were permitted to participate in the present trial, and
all signed the informed consent form. All patients had to have undergone
computed tomography (CT) of the chest with intravenous contrast and
positron emission tomography (PET) within 60 days before enrollment.
The specific CT criteria for accrual included disease confined to the
mediastinum and 1 of the following:
Tumors>8 cm in the greatest axial diameter
Tumors 5 to 8 cm in the greatest axial diameter with1 of the following
additional criteria:Irregular or scalloped borders
Heterogeneous appearance
Ectopic calcification
Obvious great vessel and/or adjacent organ invasion or encirclement
Tumors<5 cm in the greatest axial diameter with obvious great vessel
and/or adjacent organ invasion or encirclement
Patients with pleural or pericardial disease noncontiguous from the
primary site (stage IVA) were excluded. When questions arose concerning
the eligibility of a given patient, the final decision regarding inclusion was
made by the overall study principal investigator (R.J.K.). The number of
patients at each institution who met the inclusion criteria but were either
not approached to participate or refused to participate was not recorded.
Patients were not excluded unless they had not met the inclusion criteria
or had met the exclusion criteria. Appendix 1 provides a comprehensive
list of the inclusion and exclusion criteria.The Journal of Thoracic and CTreatment Regimen
The induction therapy consisted of cisplatin, etoposide, and concurrent
radiotherapy 4500 cGy. After chemoradiotherapy, the patients under-
went restaging with contrast-enhanced CT and PET. All patients without
distant progression were eligible for an attempt at surgical resection.
The operative approach was left to the discretion of the individual surgeon;
however, consistent attempts were made to perform an en bloc resection
whenever possible and to document close margins using frozen section
analysis. Resection occurred within a 4 to 8-week interval after the
completion of radiotherapy. Debulking was allowed for tumors deemed
to be grossly unresectable at surgery. Patients underwent postoperative
therapy in accordance with the study schema (Figure 1). The conduct of
the induction regimen and postoperative treatment plan has been detailed
in Appendix 2.Study Endpoints and Response Assessment
The primary endpoint was the rate of the complete pathologic
response (CPR) to the preoperative chemoradiotherapy regimen. Thus,
the pathologic evaluation of the surgical specimens, which was performed
by the individual institutional pathologists, included not only the
assignment of the World Health Organization (WHO) histologic type9
but also an estimation of the percentage of viable tumor in the specimen.
At the time of trial design, no standard protocol existed for the assessment
of viability in thymic tumors; therefore, this was performed according to
the individual institutional protocols and the judgment of the reading
pathologist. Patients with 10% of their tumor mass composed of viable
tumor were designated as having a ‘‘near CPR.’’ A post hoc examination
of all available tissue blocks and slides from the resected specimens was
performed in a blinded fashion by an independent pathology representative
(A.M.) of the International Thymic Malignancy Interest Group (ITMIG) in
an attempt to corroborate the WHO histologic type. However, the
institutional pathology assessment was used for all analyses in the present
clinical trial, as per the protocol. The secondary endpoints of the studywere
The ability of the predetermined CT criteria and maximum standardi-
zed uptake value (SUVmax) to predict the Masaoka stage
10 and
WHO histologic type
The rate of complete resection
Toxicity and surgical complications
The radiographic response to induction chemoradiotherapy using CT
and PET
Recurrence rates, failure patterns, and survival
A complete resection (R0) was defined as negative gross and micro-
scopic margins. Incomplete resections were divided into microscopically
positive margins (R1) and grossly positive margins (R2). Debulking was
considered an R2 resection.
The radiographic response was measured using CTand PET. The tumor
size was assigned according to the maximal diameter of the tumor as
measured in the axial plane on the CT scan. The post-treatment and
pretreatment sizes were compared, and the responses were classified
according to the Response Evaluation Criteria in Solid Tumors criteria.11
In addition, the magnitude of the response was calculated for each patient
using the formula: [(post-treatment size)  (pretreatment size)/pretreat-
ment size] 3 100%. The magnitude of the response to induction therapy
was also measured using PETusing the formula: [(post-treatment SUVmax)
 (pretreatment SUVmax)/pretreatment SUVmax] 3 100%.
The toxicity of the chemoradiotherapy regimen was defined using
the Common Terminology Criteria for Adverse Events, version 4.
Surgical complications were defined separately, but not graded. After
the treatment portion of the protocol, the patients were followed up every
6 months with an interim medical history, a physical examination,
PET, and CT.ardiovascular Surgery c Volume 147, Number 1 37
FIGURE 1. Study schema. CT, Computed tomography; PET, positron emission tomography; IMRT, intensity-modulated radiotherapy; 3D, 3-dimensional;
M, Monday; F, Friday; WHO, World Health Organization.
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Because of the small study size, all comparisons between medians were
performed using nonparametric tests. The Kruskal-Wallis test was used to
assess for significance among the medians of 3 groups of data, and the
Wilcoxon-Mann-Whitney test was used to assess for significance between
the medians of 2 groups. All comparisons were 2-tailed. The follow-up data
were analyzed using the Kaplan-Meier method, and the overall and
disease-free survival from the date of accrual were plotted. IBM-SPSS
Statistics software, version 19 (SPSS, Armonk, NY) was used for the
statistical analysis.RESULTS
Initial Radiographic Characteristics
A total of 22 patients were accrued at 4 institutions during
a 5-year period (July 2007 through June 2012). The median
tumor size on the CT scan was 6.8 cm (range, 5-14). A
summary of the CT inclusion criteria encountered is
presented in Table 1, and the radiographic features of
each individual tumor from the 21 patients are listed in
Table E1, along with the associated stage and WHO
histologic type. All tumors possessed abnormal uptake
on the initial PET scan, with a median initial SUVmax of38 The Journal of Thoracic and Cardiovascular Surge5.1 (range, 1.5-15). Two patients did not have the SUVmax
reported, but their tumors were noted to be hypermetabolic.
Figure 2 demonstrates the relationship between the initial
SUVmax and the final WHO histologic type. Patients with
thymic carcinoma (n ¼ 5) had a higher initial SUVmax
than did those with type B3 thymoma (n ¼ 6) or the group
with A, AB, B1, B2, and metaplastic thymoma (n ¼ 8;
P ¼ .003). No significant differences in the initial SUVmax
were appreciated between the tumors postoperatively deter-
mined to be stage I and II (n ¼ 6; median SUVmax, 4.1)
versus stage III and IV (n ¼ 13; median SUVmax, 5.3;
P ¼ .41).Conduct of Protocol and Complete Resection Rate
Of the initial 22 patients, 1 patient withdrew from the
study before beginning the induction therapy protocol. Of
the 21 patients, 17 were men (80%), and the median age
was 51 years (range, 18-78). Five patients had myasthenia
gravis (24%), and a single patient had pure red blood cell
aplasia (5%). Figure 3 demonstrates the Consolidatedry c January 2014
TABLE 1. Radiographic inclusion criteria, thoracic structures
resected, WHO histologic type, and Masaoka stage of 21 patients
undergoing attempted resection
Variable Patients (n)
Radiographic inclusion criteria
Tumor>8 cm 6 (29)
Tumor 5-8 cm
1 criterion 5 (24)
2 criteria 7 (33)
3 criteria 3 (14)
Tumor<5 cm 0
Resected thoracic structures
Pericardium 8 (38)
Lung* 8 (38)
Phrenic nerve 7 (33)
Superior vena cava 2 (10)
Diaphragm 2 (10)
Vagus nerve 1 (5)
Innominate artery 1 (5)
Sternum 1 (5)
Ribs 1 (5)
None 5 (24)
WHO histologic type
Metaplastic 1 (5)
A 2 (10)
AB 1 (5)
B1 1 (5)
B2 3 (14)
B3 6 (29)
Carcinoma 7 (33)
Postoperative Masaoka stage
I 2 (10)
II 4 (19)
III 12 (57)
IVA 1 (5)
IVB 2 (10)
Data in parentheses are percentages. WHO, World Health Organization. *Seven
wedge resections, one left pneumonectomy.
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FIGURE 2. Pretreatment maximum standard uptake value (SUV) from 21
patients with thymic epithelial tumors and its relationship to the World
Health Organization histologic type. Each data point represents an
individual patient, and the horizontal bars represent the median values.
Two patients with carcinoma did not have a maximum standard uptake
value reported. P ¼ .14, carcinoma versus B3; P ¼ .005, carcinoma versus
other; P ¼ .008, B3 versus other.
22 patients
signed consent
21 patients began
induction therapy
20 patients completed
induction therapy
21 patients
underwent resection
17 R0 3 R1 1 R2
1 withdrew
from protocol
1 refused
2nd cycle1
1 died postop3 completedpostop chemoRT
6 completed
postop chemo2 10 observed 1 died postop
1 due to myasthenia exacerbation
2 four additional patients did not complete postop chemotherapy due to patient 
refusal (n=3) and postop neutropenia (n=1)
FIGURE 3. Consolidated Standards of Reporting Trials diagram
showing the flow of patients through the protocol. Postop, Postoperative;
chemoRT, chemoradiotherapy; chemo, chemotherapy.
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patients through the protocol. Of the 21 patients who
completed preoperative radiotherapy, 3-dimensional
conformal techniques were used in 6 patients (29%) and
intensity-modulated radiotherapy in 15. The total preopera-
tive radiotherapy dose ranged from 4000 to 4500 cGy, with
17 patients (81%) receiving the maximum of 4500 cGy.
Surgical resection was attempted through a median sternot-
omy in 19 (1 reoperative), a partial sternotomy with anterior
thoracotomy (hemiclamshell) in 1, and bilateral anterior
thoracotomy with a transverse sternotomy (clamshell) in 1
patient. The additional thoracic structures resected in these
21 patients are listed in Table 1. On an intention to treat
basis, 17 patients (77%) underwent an R0 resection, 3
(14%) an R1 resection, and 1 underwent debulking (5%).
Of the 3 patients who underwent an R1 resection, 1 had
B3 thymoma and gross phrenic nerve invasion. AlthoughThe Journal of Thoracic and Can R0 resection could have been achieved by resecting the
phrenic nerve, an intraoperative decision was made not to
resect this nerve because of the patient’s history of genera-
lized myasthenia gravis, leaving a microscopically positive
margin. The single debulking was performed in 1 patient
with clear encirclement of the ascending aorta with tumor.ardiovascular Surgery c Volume 147, Number 1 39
TABLE 2. Toxicity of induction chemoradiotherapy and surgical
complications
Variable Patients (n)
Induction therapy toxicity*,y
Grade 3
Tinnitus 1 (5, 0-13)
Allergic reaction 1 (5, 0-13)
Dehydration 1 (5, 0-13)
Myasthenia gravisz 1 (5, 0-13)
Esophagitis 1 (5, 0-13)
Nausea and vomiting 1 (5, 0-13)
Febrile neutropenia 2 (9, 0-21)
Grade 4
Thrombocytopenia 1 (5, 0-13)
Cardiac arrest 1 (5, 0-13)
Surgical complicationsy
Pneumonia 1 (5, 0-13)
Pulmonary infiltrate 1 (5, 0-13)
Hemothorax 1 (5, 0-13)
Mucous plugging 1 (5, 0-13)
Aspiration 1 (5, 0-13)
Pleural effusion 1 (5, 0-13)
Intraoperative cardiac arrest 1 (5, 0-13)
Multiple organ failure 1 (5, 0-13)
Neutropenia 1 (5, 0-13)
Dressler syndrome 2 (9, 0-21)
Death 2 (9, 0-21)
Atrial fibrillation 3 (14, 0-28)
Data presented as number of patients, with the percentages and 95% confidence
intervals in parentheses. *According to Common Terminology Criteria for Adverse
Events, version 4. yPercentages calculated using intention to treat. zExacerbation
during induction therapy.
FIGURE 4. The relationship between the World Health Organization
histologic type and response to induction therapy. ‘‘Other’’ refers to type
A, AB, B1, B2, and metaplastic thymoma. A, Box and whisker plot of the
magnitude of response to induction chemoradiotherapy measured by the
tumor size on the computed tomography scan. The upper and lower ends of
each box represent the upper and lower quartiles, the thick horizontal bar
represents the median, and the extreme horizontal bars represent the
maximum and minimum values. P ¼ .09, carcinoma versus other; P ¼ .67,
carcinoma versus B3; P¼ .56, B3 versus other. B, Pathologic response to in-
duction chemoradiotherapy reported as the percentage of viable tumor in the
surgical specimens as estimated by the institutional pathologists. Each data
point represents an individual patient and the horizontal bars represent the
medianvalues. The solid points represent patients with a near complete path-
ologic response. One patient with a B3 thymoma did not have an estimate of
the percentage of viable tumor reported. P ¼ .14, carcinoma versus B3;
P ¼ .07, carcinoma versus other; P ¼ .94, B3 versus other.
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Toxicity from the induction therapy regimen (grades 3
and 4) occurred in 9 patients (41% according to the
intention to treat; Table 2). Grade 4 thrombocytopenia
developed in the single patient who had initially presented
with pure red blood cell aplasia in addition to thymoma.
The grade 4 cardiac arrest (from which the patient was
successfully resuscitated) was experienced by 1 patient
in the postanesthesia care unit after implantable port
placement for chemotherapy.
Surgical complications occurred in 8 patients (36%;
Table 2). One of the postoperative deaths occurred in a
patient with a 7.3-cm thymic carcinoma invading the
left pulmonary hilum for which pneumonectomy and
resection of both the phrenic and the vagus nerves were
required to achieve an R0 resection. The patient aspirated
in the postoperative period and died of respiratory failure.
The second death occurred in the patient with a 10.3-cm
B3 thymoma who had undergone debulking because
of encirclement of the ascending aorta. This patient
sustained an intraoperative cardiac arrest of unclear
etiology with subsequent postoperative multiple organ
system failure.40 The Journal of Thoracic and Cardiovascular SurgeRadiographic and Pathologic Response to Induction
Chemoradiotherapy
Although 20 of 21 patients experienced some degree of
radiographic tumor shrinkage from the induction therapy
regimen as determined by CT (Table E1), only 10 patients
met the criterion for a partial radiographic response
according to the Response Evaluation Criteria in Solid
Tumors. An additional 11 patients had stable disease,
no patient progressed radiographically, and no patient
achieved a complete radiographic response. A trend
was seen toward a greater magnitude of radiographic
response as measured by the tumor size (Figure 4, A) in
the 7 patients with thymic carcinoma compared with the
8 patients with A, AB, B1, B2, and metaplastic thymoma
(28% vs 15%; P ¼ .09).
The SUVmax decreased in 18 patients and increased in
1 patient after induction chemoradiotherapy (Table E1).ry c January 2014
FIGURE 5. Freedom from progression and actuarial overall survival after multimodality treatment of locally advanced thymoma and thymic carcinoma.
The vertical bars indicate 95% confidence intervals. A, Freedom from progression. B, Overall survival.
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in their PET scan readings. The median magnitude of
change in the SUVmax after induction therapy was
44.5%, with 5 patients (24%) having complete
normalization of their PET scans after induction therapy
(2 with carcinoma, 2 with type B2, and 1 with type B1).
Despite this normalization, only 2 of these (both with
carcinoma) had a near CPR. No significant differences
were noted in the median magnitude of the response
as measured using the SUVmax according to the WHO
histologic type (carcinoma, 39%; B3 thymoma,
45%; A, AB, B1, B2, and metaplastic thymoma,
43.5%; P ¼ .91).
The postoperative Masaoka stage and WHO histologic
type (from the institutional pathologists) of the 21 patients
who underwent attempted resection are listed in Table 1.
All patients had viable tumor in their surgical specimen
(Table E1). The relationship between the WHO histologic
type and pathologic response to the induction regimen is
displayed in Figure 4, B. Despite the lack of any CPR to
the induction chemoradiotherapy, 5 patients (24%) were
deemed to have a near CPR.
Paraffin-embedded tissue blocks or slides were made
available for 16 of the 21 resected specimens for the
blinded ITMIG pathologist to perform a post hoc
review; however, only 15 of these had enough material
to satisfactorily establish the WHO histologic type. In 9
of 15 cases, the ITMIG pathology assessment was
concordant with the institutional pathology report, with
6 discordant. In 4 of the discordant cases, the difference
in the interpretation was considered ‘‘minor’’ (eg, B2 vs
B1; A vs AB). In the other 2 discordant cases (A vs B2;
A vs B3), the ITMIG pathologist performed additional
immunohistochemistry testing (CD20), which led to the
discordance.The Journal of Thoracic and CRecurrence and Survival
With a median follow-up of 27 months (range, 0-64) for
the entire treated cohort, no patient who underwent a
complete resection had experienced recurrence. Thus, the
freedom from recurrence rate was 100% in the completely
resected patients. Of the 19 patients who survived into the
follow-up period, 15 were alive without recurrence, 1 was
alive with persistent disease (pleura, liver), 1 had died of
persistent and/or progressive tumor (lung, mediastinum,
pulmonary hilum), 1 had died of pneumonia without
recurrence, and 1 was lost to follow-up. Both patients
with persistent and/or progressive disease had undergone
an R1 resection and had received chemotherapy once they
had developed progression. At 60 months after the date of
resection, the freedom from progression and overall
actuarial survival of the entire 22-patient cohort was 83%
and 71%, respectively (Figure 5).DISCUSSION
Utility of CT and PET in Predicting Masaoka Stage
and WHO Histologic Type
The Masaoka staging system relies on information
obtained at the resection and pathologic examination,
making the preoperative identification of Masaoka stage
III thymic tumors inconsistent at best. Thus, previously
published induction therapy trials have been difficult to
compare with each other, because no specific radiographic
inclusion criteria were used. Also, the tumors have
generally been described using highly subjective terms
(eg, ‘‘unresectable’’).2,3
In the present trial, specific CT radiographic criteria were
developed in an attempt to preoperatively identify patients
with tumors at greater risk of recurrence (‘‘high-risk’’
disease) and hopefully standardize the inclusion of patientsardiovascular Surgery c Volume 147, Number 1 41
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criteria were determined from previously published CT
features of invasive thymoma,12 some of which are
subsequently being evaluated by the ITMIG.13 Of the 21
patients, 71% were confirmed to have locally advanced
tumors (Masaoka stage III and IV) when these criteria
were applied, a percentage that was likely greater given
that patients all had undergone chemoradiotherapy before
staging (Table 1). Similarly, these criteria also seemed to
select patients with high-risk tumors according to the
WHO histologic type, with 62% having either thymic
carcinoma or B3 thymoma. These findings suggest that
specific CT criteria can be used to identify patients with
high-risk thymic tumors.
The ability of PET to identify patients with high-risk
tumors was also evaluated in the present trial. Although
the use of SUVmax as a quantitative measure for risk
stratification of malignant tumors has been associated
with inherent subtle variations in scan technique and
biologic variables, which can affect its value,14 the
presented data showed a striking relationship between the
SUVmax and WHO histologic type, with the highest risk
tumors possessing the greater SUVmax values, despite the
small sample sizes (Figure 2). This observation has been
previously reported in some retrospective studies.15-17
From these data, the use of PET to stratify preoperative
risk in patients with thymic tumors is worthy of additional
evaluation.
Addition of Radiotherapy to Induction
Chemotherapy
The rationale for the addition of radiotherapy to induc-
tion chemotherapy in the present trial was to attempt
to enhance the rate of complete resection and the
pathologic response compared with induction chemo-
therapy alone.18 The observation that only 6 patients did
not meet the criteria for a radiographic response or a near
CPR, yet still underwent an R0 resection, suggests that
most patients might have benefitted from the induction
regimen.
The 2 largest prospective clinical trials published to date
using induction chemotherapy alone for thymoma reported
a complete resection rate of 43% (9 of 21) and 73% (16 of
22) when analyzed according to the intention to treat.2,3 The
results from the present study compare favorably with the
former 2 studies at 77% (17 of 22); however, these 3
trials differed significantly in multiple factors, including
the radiographic and pathologic inclusion criteria,
Masaoka stage, chemotherapeutic agents, and assessment
of the radiographic response. In the Japanese Clinical
Oncology Group 9606 trial,3 the patients had ‘‘unresect-
able’’ tumor localized to the mediastinum, but patients
with thymic carcinoma were excluded. Similarly, Kim
and colleagues2 included patients deemed ‘‘unresectable’’42 The Journal of Thoracic and Cardiovascular Surgebut also included patients with stage IVA and excluded
those with thymic carcinoma.
The toxicity of the induction chemoradiotherapy regimen
was generally acceptable, with all but 1 patient completing
the regimen. This was similar to the induction chemo-
therapy study reported by Kim and colleagues,2 in which
20 of 22 patients completed the induction regimen.
However, it was significantly different from the Japanese
Clinical Oncology Group 9606 trial in which only 57%
of patients completed the induction chemotherapy.3
Treatment-related mortality in the present study consisted
exclusively of 2 postoperative deaths that appeared to be
related to the surgical procedure itself and not the
preoperative treatment regimen. In contrast, the single
treatment-related death report by Kim and colleagues2
occurred during the adjuvant therapy portion of the
regimen. The Japanese Clinical Oncology Group 9606 trial3
reported no treatment-related mortality.
An unexpected finding was the lack of any CPR to
induction chemoradiotherapy in the present trial, despite
24% of the patients having a near CPR. The 2 previously
discussed trials reported a CPR rate of 10% and 14% using
chemotherapy alone.2,3 Intuitively, it would be expected
that the addition of radiotherapy would increase the
number of CPRs, but this did not occur. Explanations for
this finding include differences in the chemotherapy
regimens (although all were cisplatin-based), the
pathologic assessment, and, possibly, differences in the
histologic type, although this remains to be determined.
The present study revealed a trend toward a greater
magnitude of response (as measured by CT) in the
patients with thymic carcinoma compared with the group
with A, AB, B1, B2, and metaplastic thymomas (Figure 4,
A). This is even more intriguing when one considers that
4 of the 5 patients with a near CPR had thymic carcinoma.
These findings imply that patients with high-risk WHO
histologic types might respond the best to this induction
chemoradiotherapy protocol. This observation is worthy
of additional study and clearly emphasizes the need to
appropriately select future high-risk patients for induction
therapy.
Study Strengths and Limitations
The clear strength of the present study is that it represents
a formal, prospective clinical trial for a rare disease with
rigorous data collection and quality. An additional strength
was the objective CT criteria used for patient selection. By
avoiding subjective terms such as ‘‘unresectable,’’ these
inclusion criteria can be applied to future locally advanced
thymoma trials and the outcomes more readily compared.
A major limitation of the present study was the small
sample size, not surprising, given the rarity of these tumors.
This small sample size limited some of the conclusions that
can be drawn from the data such as a strict definition of ary c January 2014
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Another limitation was in the ability of the imaging criteria
to predict the Masaoka stage. Because the patients had
received induction therapy, their stage could have changed
by the time they underwent resection. Despite this, it seems
more likely than not that these patients’ disease did not
progress during the induction protocol, because no tumors
had enlarged, and the vast majority had regressed in size.
Therefore, it follows that the patients’ disease stages were
at least as advanced at presentation compared with at
surgery. Finally, the pathologic examinations were limited
by the use of individual institutional pathology examina-
tions. Ultimately, the best study design would be to have
a single pathologist review all the specimens and use an
established protocol for estimating the amount of viable
tumor in each specimen. However, no such protocol
for thymic tumors existed when the present trial was
designed.
CONCLUSIONS
The present study has demonstrated that induction
chemoradiotherapy is a viable option for patients with
locally advanced thymic tumors and that its use results in
a high rate of complete surgical resection. In addition,
specific CT findings (ie, large tumor size, irregular borders,
heterogeneous appearance, ectopic calcification, obvious
great vessel or adjacent organ invasion and/or encirclement)
and PET criteria (high SUVmax) appear to be able to
select patients who ultimately have locally advanced
Masaoka stages and high-risk histologic types (B3 and
carcinoma).
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Age 18 years
Male or female
Karnofsky performance status>80%
Biopsy-proven thymoma, including carcinoma; biopsy
could be obtained by multiple approaches, including
fine needle aspiration for cytology, transcutaneous
core needle biopsy, or open, thoracoscopic, or
mediastinoscopic biopsy, with the latter 2 techniques
preferred
Biopsy slides must be reviewed by pathologists at
participating institutions and assigned a WHO
classification wherever possible based on the biopsy
material
Patients must have a CT scan of the chest with
intravenous contrast within 60 days of enrollment
Tumors>8 cm in the greatest diameter on the CT scan
For tumors 5-8 cm in the greatest diameter on the CT
scan, 1 of the following radiographic criteria
must also be present on the intravenous contrast-
enhanced CT scan:arMultifocal calcification
Heterogeneous appearance
Irregular or scalloped borders
Obvious great vessel invasion or encirclement
For tumors <5 cm in the greatest diameter on the
CT scan, obvious great vessel invasion and/or
encirclement must be present on the CT scan
Patients with anterior mediastinal carcinoma unable to
be further differentiated and who have no evidencediovascular Surgery c Volume 147, Number 1 43
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Sof another primary tumor site or metastatic spread
beyond the mediastinum
Pulmonary function acceptable for surgery according to
institutional criteria
Laboratory criteria (within 30 days of enrollment):
Absolute neutrophil count 1500/mL
Platelet count 100,000
Total bilirubin and aspartate aminotransferase/alanine
aminotransferase1.5 times the institutional upper
limit of normal
Creatinine clearance 50 mL/min (calculated using
institutional standard)Exclusion Criteria
Patients thought to be unable to medically tolerate surgi-
cal resection as assessed at the initial presentation
Hypersensitivity to cisplatin and/or etoposide
Patients with radiographic evidence of stage IVA thy-
moma (pleural or pericardial disease noncontiguous
with the primary tumor site)
Pretreatment biopsy showing WHO type A thymoma
when reviewed by institutional pathologists, un-
less obvious great vessel invasion and/or encircle-
ment is present on the CT scan; it is understood
that a WHO subtype might not be able to be
assigned on the basis of the biopsy specimen in
all cases
Previous radiotherapy to the chest that would preclude
the administration of radiation using 3-dimensional
conformal or intensity-modulated radiotherapy plan-
ning
Significant medical or psychiatric illness that would
interfere with patient compliance
Patients whose 3-dimensional radiotherapy plan cannot
meet the dose–volume constraint
Patients receiving other investigational drugs
Pregnant women or women of childbearing potential
(women are not considered of childbearing potential
if they are2 years postmenopausal and/or surgically
sterile) who refuse to use effective contraception; will
be determined on the judgment of the institutional
principal investigators or designated associates
Failure to meet inclusion criteriaAPPENDIX 2. INDUCTION REGIMEN
Cisplatin was administered by continuous intravenous
infusion for 1 hour on days 1, 8, 29, and 36 at a dose of
50 mg/m2. The patients were hydrated both before and afterThe Journal of Thoracic and Cardiovascular Surgecisplatin dosing with mannitol and saline. The use of
colony-stimulating factors was prohibited. Etoposide was
administered by continuous intravenous infusion for 1
hour on days 1 to 5 and 29 to 33 at a dose of 50 mg/m2.
Dosage modifications, including reductions and delays,
were incorporated into the protocol for hematologic
toxicity, if the creatinine clearance decreased to<50 mL/
min, and/or grade 3 or 4 nonhematologic toxicity.
Preoperative radiotherapy began within 24 hours of
chemotherapy initiation using either a 3-dimensional
conformal–or intensity-modulated radiotherapy–based
plan. The radiation dose was 4000 to 4500 cGy at 180 to
200 cGy/fraction (weeks 1-5; Monday through Friday).
The treatment target included the entire thymus and the
gross tumor, with a 2 to 2.5-cm margin. To minimize
toxicity, dose–volume constraints were incorporated into
the radiation plan for the lungs, esophagus, heart, and spinal
cord. Radiotherapy interruptions were permitted for febrile
neutropenia, grade 4 mucositis or esophagitis, and grade
3-4 pulmonary toxicity.
Postoperative Treatment
Patients undergoing adjuvant chemotherapy alone
received cisplatin by continuous intravenous infusion for
1 hour on days 1 to 3 and 29 to 31 at a daily dose of
33 mg/m2. Patients were hydrated both before and after
cisplatin dosing with mannitol and saline. Etoposide was
administered by continuous intravenous infusion for 1
hour on days 1 to 3 and 29 to 31 at a dose of 100 mg/m2.
Patients undergoing adjuvant chemoradiotherapy (patients
with incomplete resection) received the same treatment
protocol used in the preoperative setting, except that
only an additional 2000 to 2500 cGy of radiation (180 to
200 cGy/fraction; ending during the third treatment week)
was administered to the sites of residual disease. In these
cases, the chemotherapy dose for the second postoperative
cycle was increased to the level administered in the
absence of radiotherapy (cisplatin 33 mg/m2 and etoposide
100 mg/m2 on days 29-31).Discussion
Dr Frank C. Detterbeck (New Haven, Conn). Bob, nice
presentation. I want to thank you for pulling this off. This was
really Bob’s trial that he initiated, and I think to pull off a
multicenter trial with multiple institutions and a rare disease
such as thymoma is really an accomplishment, and I think that is
great. There really are not all that many prospective series out
there. I think that is 1 of the strengths of this study—it is a
multicenter trial, and it is prospective. I think another major
strength is that the patients are really quite well characterized by
the radiographic findings. I think all too often we are limited by
reading reports. One walks away from the report, saying, ‘‘well,
that is interesting, but I really do not have a strong clue about
what these patients really looked like and whether a patient I amry c January 2014
Korst et al General Thoracic Surgery
G
T
Sseeing is going to be similar to what was reported.’’ Thus, I think
those are the real strengths of what you reported, and, certainly, the
lack of any recurrence in those who underwent complete resection
is pretty exciting.
My first question is about the choice of chemoradiotherapy
versus chemotherapy. I did a brief review of the studies that
have been published on induction chemotherapy, certainly patients
who were not quite as well characterized but had stage III
thymoma or thymic carcinoma, and I think that your complete
resection rate was pretty similar, 77% versus 75%. Your survival
was pretty similar at 5 years, 71% versus 74%. However, your
CPR rate was lower, 0% versus 18% in the other studies, and the
partial response rate was lower also, about 46% versus 89%. So
I am not necessarily seeing a benefit as I would have expected
from chemoradiotherapy, and I am wondering about your thoughts
about that.
Dr Robert J. Korst. Thank you, Dr Detterbeck.
We had the same impression as well. There have been a couple
of CPRs in at least 1 of the other prospective clinical trials of this
disease, but we did not see any, despite the addition of another
locally acting agent. We did, however, have 5 near CPRs in the
patients with thymic carcinoma. I think from a toxicity standpoint,
we are in the ballpark with chemotherapy alone. I do not think our
study had significantly more toxicity than some of the other
published data. The studies, however, were drastically different
in terms of the stages included and other inclusion criteria. The
patients had been deemed unresectable in the other 2 prospective
studies, but that is a highly subjective term. In addition to that,
the chemotherapy agents were different. One of the studies was
actually a chemotherapy and prednisone study. Thus, it is really
difficult to make comparisons.What we tried to dowith the present
study was to try and make some of these factors as objective as
possible, such that in the future, when other studies are done, the
data can be compared.
It is hard to say I am going to change my practice because of a
22-patient prospective, single-arm trial, but it is all we have in
thymoma. I have always treated with preoperative chemotherapy
for locally advanced thymoma; however, the data for the thymic
carcinoma are intriguing. Of the 7 patients, 4 had a near CPR. It
is also the patients with thymic carcinoma who also had the
most significant radiographic response. Therefore, if I had a
patient with thymic carcinoma who presented to me and met these
criteria, I would probably treat them with chemoradiotherapy up
front.
Dr Detterbeck.My next question is where do we go from here?
This is an intriguing trial, 20 patients. It is slightly more difficult to
really know for sure whether it is chemoradiotherapy versus
chemotherapy, et cetera, et cetera, what is really the way to go
and how do we get more science behind what we should be doing
as we move forward.
Dr Korst.Well, what we really need to do is band together and
start doing trials in this rare disease. I can tell you that I shopped
this trial around to anyone who would listen 5 years ago, and the
response was always similar, which was, ‘‘We are going to see 2
patients this year. It is really not worth our while to get this through
our institutional review board.’’ We have to change that, and if we
can change that, we can start investigating all types of questions for
these patients.The Journal of Thoracic and CDr Scott J. Swanson (Boston, Mass). I really enjoyed it, Rob.
Without seeing the scans, it is hard for us to know what you
were looking at. How comfortable are you that these patients
had unresectable disease before treatment and is there some other
minimally invasive method we should use to ensure that? Because
if 4 or 5 of these patients had resectable disease before this
treatment, perhaps they did not need this intensive therapy up
front.
DrKorst.Well, that is clearly a good point, and I will be the first
to tell you that unresectability was not an inclusion criterion. There
were some patients who, if you looked at the scan, you would say,
‘‘I could probably take that out,’’ and then there actually were some
patients who had terrible disease. The remainder of the patients
were all kind of on that fence. One third of the patients had
clear-cut great vessel or organ invasion, indicating an intraluminal
tumor. It is hard to make comparisons in this disease because my
‘‘unresectable’’ might not be your ‘‘unresectable.’’
Dr Swanson. I have 1 last follow-up question. Carcinoma
sounds clear and clear-cut invasion sounds clear. If you have a
patient you are not so sure about now but who fits these criteria,
would you give them the induction therapy or would you try to
resect them, you know, off the protocol?
Dr Korst. If I was treating off the protocol, I think what I would
do is probably treat with preoperative chemotherapy for patients
with marginally resectable disease at this point, unless they were
a patient with carcinoma or perhaps B3, for whom I would use
chemoradiotherapy.
Dr Swanson. So nobody progresses. You do not lose the ability
to resect anybody.
Dr Korst. No one progressed.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). I have just a
comment to Scott’s question. When you consider the survival
curves of thymoma and you consider the ones that we resect that
recur later, that was sort of the target we were looking at, the
high risk of recurrent tumors or a high risk of incomplete resection.
So, the patients who you see clearly do not have resectable disease
and ‘‘let us try and treat them and see whether we can make them
resectable’’ were not really the target for this trial. It was more the
high-risk larger tumors in general, but not necessarily just large,
and then showing invasive or aggressive features, to see whether
we could improve on that. The pleasant surprise was how well
the thymic carcinomas behave with this induction therapy.
So, those were 2 important nuances.
Dr Jacques-Pierre Fontaine (Tampa, Fla).Of the 23% of your
patients who did not undergo an R0 resection, what percentage
were able to receive postoperative radiotherapy for those positive
margins, seeing that they all had already received 4000 to 4500
cGy preoperatively? As a follow-up comment, if your trial
does not show an increased rate of R0 resectability or a change
in survival compared with previous series, albeit not truly
comparable, why not simply give them induction chemotherapy
only, resect, and treat your R1 and R2 resections with higher
doses of uninterrupted postoperative radiotherapy, which would
be more effective than lower doses or interrupted doses of
radiation?
Dr Korst. Of the patients who did not undergo an R0 resection,
1 underwent debulking and died postoperatively, but the other
4 were treated.ardiovascular Surgery c Volume 147, Number 1 45
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despite the initial radiation?
Dr Korst. They were able to be treated. Again, it is a matter of
philosophy. The purpose of the trial was to try to enhance our rate
of complete resection by adding another local modality. It is
unfortunate that the trials are really not comparable. The other
trials excluded patients with thymic carcinoma. One third of our
patients had carcinoma. You just cannot compare the patients.
Dr Dirk Van Raemdonck (Leuven, Belgium). With regard to
your pretreatment staging, did you do thoracoscopy in any of these
patients or in all patients to exclude stage IVA disease?
Dr Korst. No. It was all done radiographically. A single patient
was found to have stage IVA disease once they had undergone
resection. Also, we had 2 patients who had stage IVB because of
nodal disease.
Dr Joshua R. Sonett (New York, NY). It was a great endeavor
and great project, with results that I think will be extremely46 The Journal of Thoracic and Cardiovascular Surgehelpful. One question that I have encountered is trying to sort
out the large thymomas that will not respond to induction
therapy and, thus, should avoid induction. Thus, using pathol-
ogy or molecular studies, we need to separate out who should
receive therapy for thymoma. I have had a number of patients
with very large thymomas that had very disappointing results
from induction chemotherapy. I am wondering whether you
could glean anything from your data that indicates which of
those thymomas responded and which did not, because if they
are not going to respond, clearly, the whole debate about
whether to go straight to surgery or give them induction is
less relevant.
Dr Korst. Most type A thymomas can be resected. I think
the WHO histologic type plays a large role in the decision.
However, the carcinoma or B3 cases, I think those are
the ones for which one must entertain the idea of induction
therapy.ry c January 2014
TABLE E1. Tumor details of 21 individual patients on the protocol
Pt. ID*
Tumor
size (cm)y
Initial
SUVmaxz CT criteria
WHO histologic
typex
Change in
tumor size (%)jj
Change in
SUVmax (%)
Resection
status Stage{
Viable
tumor# (%)
715-01 5 4.2 Lobulated
Heterogeneous
B3 0 52 R0 III 10
715-02 8.3 5.4 Lobulated
BCV invasion
Metaplastic 12 48 R0 II 100
715-03 6.1 8.7 Lobulated
Heterogeneous
IA invasion
C 25 28 R1 IVB 80
715-04 8 5.1 Lobulated
Heterogeneous
B3 50 41 R0 III 90
715-05 10.3 11.2 Lobulated
Heterogeneous
AA encirclement
B3 5 36 R2 III 100
715-06 7.5 6.3 Calcified
Heterogeneous
SVC invasion
B3 39 49 R1 III 100
715-07 7.2 3.9 Heterogeneous
Calcified
B2 8 10 R0 I 100
715-08 14 2.9 Lobulated
Heterogeneous
Calcified
AB 32 7 R0 III 75
715-09 5.1 3.5 Lobulated
Heterogeneous
B2 2 100 R0 II 95
715-10 7 3.7 Lobulated B2 43 100 R0 III 80
715-11 5.6 4.6 Lobulated B3 30 25 R0 III NR
715-12 6.3 5.3 Lobulated C 19 39 R0 III 10
715-13 6.7 3.3 Lobulated
Heterogeneous
A 3 39 R0 II 85
712-01 5 10.1 Heterogeneous
Paralyzed diaphragm
C 54 100 R0 III 10
712-02 9 1.5 Heterogeneous A 17 þ87 R0 III 15
712-03 6.6 4.2 Lobulated
Heterogeneous
B1 36 100 R0 II 40
714-01 5.3 NR Lobulated
Heterogeneous
C 43 NR R0 III 95
714-02 6.6 NR Lobulated
Heterogeneous
IA encirclement
C 28 NR R1 IVB 10
717-01 7.3 15 Lobulated
Main PA invasion
C 23 37 R0 III 80
717-02 6.8 14 SVC encirclement C 41 100 R0 I 1
717-03 14 6.5 Lobulated
Heterogeneous
Calcified
RML invasion
B3 36 72 R0 IVA 40
Pt. ID, Patient identification; SUVmax, maximum standard uptake value;CT, computed tomography;WHO,World Health Organization;BCV, brachiocephalic vein; IA, innominate
artery; AA, ascending aorta; SVC, superior vena cava; NR, not reported; PA, pulmonary artery; RML, right middle lobe of the lung. *University of Toronto, n ¼ 715; The Valley
Hospital, n ¼ 712; Massachusetts General Hospital, n ¼ 714; Methodist Hospital, n ¼ 717. yMeasured on initial CT scan. zFrom the initial PET scan; all values higher than the
mediastinal blood pool. xFrom resected specimen. jjMeasured on CT scan. {Postoperative Masaoka stage. #Estimated by institutional pathologists.
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